Psoriatic arthritis (PsA) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)

Publication ⇒ Jan -24    Delivery Time ⇒ 5-7 Business Days   Report Code ⇒PBCHC193-8M-TR

License Type (Price in USD)

Psoriatic arthritis (PsA) Market – Report Overview

Pacific Business Consulting’s “Psoriatic Arthritis (PsA) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)” report offers a comprehensive understanding of Psoriatic arthritis (PsA), encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

In 2021, the psoriatic arthritis market size in the 8MM (Eight Major Markets) reached approximately US$9.8 billion. The United States holds the largest share in the psoriatic arthritis market, followed by the U.K., Germany, Italy, France, Spain, Japan, and China.

Psoriatic arthritis (PsA) is a type of arthritis associated with psoriasis, a chronic skin and nail disease characterized by red, scaly rashes and thick pitted fingernails. Psoriatic arthritis shares symptoms of joint inflammation with rheumatoid arthritis (RA), although it typically affects fewer joints and does not produce typical RA antibodies. The etiology and pathogenesis of PsA involve a complex interplay between genetic and environmental factors, resulting in immune-mediated inflammation affecting the skin and joints and possibly other organs. A significant percentage of PsA patients have at least one first-degree relative with psoriasis or PsA. Genes associated with PsA include those in the HLA region involved in antigen presentation and immune recognition, as well as non-HLA genes related to immune activation, inflammation, intracellular signaling, cytokine expression, and T-cell effector function. Although suspected, confirming the role of environmental factors has been challenging. Psoriatic skin lesions can be induced by skin trauma, known as the Koebner phenomenon, and joint trauma may lead to arthritis flares, termed the “internal” or “deep” Koebner phenomenon.

To meet current patient demands and address unmet needs in the therapeutic market, drug developers are increasingly focusing on PsA. Several companies are actively working on new therapies, including bimekizumab (UCB Biopharma), tildrakizumab (Sun Pharmaceutical), deucravacitinib (BMS), and izokibep (Affibody AB). Bimekizumab (UCB Biopharma) is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes, with IL-17F having overlapping biology with IL-17A.

Key players in the segment include UCB Biopharma, BMS, Affibody AB, Janssen Biotech, Sun Pharmaceutical Industries Limited, Amgen, AbbVie, Pfizer, and Eli Lilly and Company.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Psoriatic arthritis market. It also delves into the analysis of present and prospective market competition within the global Psoriatic arthritis market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

  • Develop your business strategies by gaining insights into the trends that shape and drive the Psoriatic arthritis market across the 8MM (Eight Major Markets).
  • Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Psoriatic arthritis market.
  • Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
  • Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

  1. Executive Summary: Psoriatic arthritis (PsA)
    • Global Market Outlook: Psoriatic arthritis (PsA)
  2. Competitive Intelligence Analysis: Psoriatic arthritis (PsA)
  3. Therapeutic Sector SWOT
  4. Technology Roadmap Analysis: Psoriatic arthritis (PsA)
  5. Market Background
    • Drivers
    • Restraints
    • Opportunity
    • Key Market Trends
    • Key Unmet Needs
  6. Disease Overview: Psoriatic arthritis (PsA)
    • Disease Etiology
    • Pathophysiology
    • Risk Factors
    • Treatment Algorithm
  7. Psoriatic arthritis (PsA): Key Marketed Products Profile – Major Approved Products
    • Product Profile
    • Regulatory Milestones
    • Safety and Efficacy
    • Clinical Development
  8. Psoriatic arthritis (PsA): Promising Pipeline Candidates – Major Products in Late Stage of Development
    • Product Description
    • Safety and Efficacy
    • Research and Development
  9. Regulatory Landscape
  10. Psoriatic arthritis (PsA): Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  11. S. Psoriatic arthritis (PsA) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  12. K. Psoriatic arthritis (PsA) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  13. Germany Psoriatic arthritis (PsA) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  14. France Psoriatic arthritis (PsA) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  15. Italy Psoriatic arthritis (PsA) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  16. Spain Psoriatic arthritis (PsA) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  17. Japan Psoriatic arthritis (PsA) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  18. China Psoriatic arthritis (PsA) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

  1. Assumptions and Acronyms Used
  2. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
  3. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China
  4. Copyrights and Disclaimer

Customize Reports As Per Your Needs

Don’t see what you’re looking for? Get a report tailored to your specific requirements. Customize your report now!

Have A Question?

We are happy to assist you.

Phone:+919599779105
Email:info@pacificbusinessconsulting.com